Just a moment, the page is loading...

GSK-444563/007 (rota-007)




Study to assess efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Bio’s oral live attenuated human rotavirus vaccine at different viral concentrations in healthy infants previously uninfected with human rotavirus and approximately 3 months of age
Rotavirus Vaccine
444563/007 (rota-007)
NCT00429481
Infections, Rotavirus
Phase 2
An annotated case report form is not available for this study. A blank case report form will be provided.
June 2015